alexa Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Lodise TP, McKinnon PS

Abstract Share this page

Abstract We performed a retrospective cohort study to determine the morbidity, mortality, and hospital costs attributable to methicillin resistance in patients with S. aureus bacteremia (SAB). Episodes of SAB occurring at the Detroit Receiving Hospital in 1999-2001 were evaluated. Controlling for confounding variables, patients with methicillin-resistant Staphylococcus aureus (MRSA) had a 1.5-fold longer length of stay (19.1 versus 14.2 days, P = 0.005) and a 2-fold increased cost of hospitalization (dollar 21577 versus dollar 11668, P = 0.001) compared with methicillin-susceptible S. aureus (MSSA). MRSA patients were at increased risk for delayed treatment, and delayed therapy was an independent predictor of mortality. Efforts should be made to ensure that appropriate therapy is initiated promptly in patients at risk for MRSA. Infection control policies must be strictly enforced to limit the spread of MRSA and potentially minimize excess hospital expenditures incurred with MRSA. With the advent of new treatment options, the impact of MRSA will need to be revisited to determine if these therapies can remedy the increased morbidity associated with MRSA. This article was published in Diagn Microbiol Infect Dis and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version